Similar to the HL trial, the trial's primary endpoint was objective response rate.

In the risperidone trial, just over half of the children with GI problems showed a positive response to treatment compared to 75 percent of those with no history of GI problems.

There was no difference in the rate of positive response in the methylphenidate trial.